316 related articles for article (PubMed ID: 26440450)
1. Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
Heurling K; Leuzy A; Zimmer ER; Lubberink M; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):362-373. PubMed ID: 26440450
[TBL] [Abstract][Full Text] [Related]
2. Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
de Lartigue J
Drugs Today (Barc); 2014 Mar; 50(3):219-29. PubMed ID: 24696867
[TBL] [Abstract][Full Text] [Related]
3. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
[TBL] [Abstract][Full Text] [Related]
4. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
5. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
[TBL] [Abstract][Full Text] [Related]
6. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease.
Snellman A; Rokka J; Lopez-Picon FR; Eskola O; Wilson I; Farrar G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1784-95. PubMed ID: 22801729
[TBL] [Abstract][Full Text] [Related]
9. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
[TBL] [Abstract][Full Text] [Related]
10. Florbetapir F 18 for brain imaging of β-amyloid plaques.
Romano M; Buratti E
Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
[TBL] [Abstract][Full Text] [Related]
11. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.
Ito H; Shinotoh H; Shimada H; Miyoshi M; Yanai K; Okamura N; Takano H; Takahashi H; Arakawa R; Kodaka F; Ono M; Eguchi Y; Higuchi M; Fukumura T; Suhara T
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):745-54. PubMed ID: 24233004
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
Morris E; Chalkidou A; Hammers A; Peacock J; Summers J; Keevil S
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):374-385. PubMed ID: 26613792
[TBL] [Abstract][Full Text] [Related]
13. Amyloid PET Imaging: Standardization and Integration with Other Alzheimer's Disease Biomarkers.
Morbelli S; Bauckneht M
Methods Mol Biol; 2018; 1750():203-212. PubMed ID: 29512074
[TBL] [Abstract][Full Text] [Related]
14. Distinct binding of amyloid imaging ligands to unique amyloid-β deposited in the presubiculum of Alzheimer's disease.
Ji B; Chen CJ; Bando K; Ashino H; Shiraishi H; Sano H; Kasahara H; Minamizawa T; Yamada K; Ono M; Zhang MR; Seki C; Farde L; Suhara T; Higuchi M
J Neurochem; 2015 Dec; 135(5):859-66. PubMed ID: 26315807
[TBL] [Abstract][Full Text] [Related]
15. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.
Nelissen N; Van Laere K; Thurfjell L; Owenius R; Vandenbulcke M; Koole M; Bormans G; Brooks DJ; Vandenberghe R
J Nucl Med; 2009 Aug; 50(8):1251-9. PubMed ID: 19617318
[TBL] [Abstract][Full Text] [Related]
17. Estimation of amyloid distribution by [
Thal DR; Beach TG; Zanette M; Lilja J; Heurling K; Chakrabarty A; Ismail A; Farrar G; Buckley C; Smith APL
Acta Neuropathol; 2018 Oct; 136(4):557-567. PubMed ID: 30123935
[TBL] [Abstract][Full Text] [Related]
18. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
[TBL] [Abstract][Full Text] [Related]
19. Current status of PET-imaging probes of β-amyloid plaques.
Koo J; Byun Y
Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777
[TBL] [Abstract][Full Text] [Related]
20. [(18)F]Florbetaben: a review in β-amyloid PET imaging in cognitive impairment.
Syed YY; Deeks E
CNS Drugs; 2015 Jul; 29(7):605-13. PubMed ID: 26175116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
